These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 33367372)
61. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Carter L; Fouser LA; Jussif J; Fitz L; Deng B; Wood CR; Collins M; Honjo T; Freeman GJ; Carreno BM Eur J Immunol; 2002 Mar; 32(3):634-43. PubMed ID: 11857337 [TBL] [Abstract][Full Text] [Related]
62. Melanoma Cancer Immunotherapy Using PD-L1 siRNA and Imatinib Promotes Cancer-Immunity Cycle. Li C; Han X Pharm Res; 2020 May; 37(6):109. PubMed ID: 32476052 [TBL] [Abstract][Full Text] [Related]
63. Tanshinol suppresses cardiac allograft rejection in a murine model. Lu C; Zeng YQ; Liu H; Xie Q; Xu S; Tu K; Dou C; Dai Z J Heart Lung Transplant; 2017 Feb; 36(2):227-236. PubMed ID: 27574736 [TBL] [Abstract][Full Text] [Related]
64. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors. Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968 [TBL] [Abstract][Full Text] [Related]
65. Immunotherapy of alveolar echinococcosis via PD-1/PD-L1 immune checkpoint blockade in mice. Wang J; Jebbawi F; Bellanger AP; Beldi G; Millon L; Gottstein B Parasite Immunol; 2018 Dec; 40(12):e12596. PubMed ID: 30315719 [TBL] [Abstract][Full Text] [Related]
66. Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity. Wang B; Zhou Y; Zhang J; Jin X; Wu H; Huang H Theranostics; 2020; 10(3):1033-1045. PubMed ID: 31938049 [No Abstract] [Full Text] [Related]
67. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy. Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033 [TBL] [Abstract][Full Text] [Related]
68. Intratumoral Delivery of an Adenoviral Vector Carrying the Nakagawa S; Serada S; Kakubari R; Hiramatsu K; Sugase T; Matsuzaki S; Matsuzaki S; Ueda Y; Yoshino K; Ohkawara T; Fujimoto M; Kishimoto T; Kimura T; Naka T Mol Cancer Ther; 2018 Sep; 17(9):1941-1950. PubMed ID: 29891489 [TBL] [Abstract][Full Text] [Related]
69. The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response. Luo M; Fu L Oncotarget; 2016 May; 7(20):29794-803. PubMed ID: 26919108 [TBL] [Abstract][Full Text] [Related]
70. Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice. Gotsman I; Grabie N; Dacosta R; Sukhova G; Sharpe A; Lichtman AH J Clin Invest; 2007 Oct; 117(10):2974-82. PubMed ID: 17853943 [TBL] [Abstract][Full Text] [Related]
71. Immunosuppression of Human Adipose-Derived Stem Cells on T Cell Subsets via the Reduction of NF-kappaB Activation Mediated by PD-L1/PD-1 and Gal-9/TIM-3 Pathways. Zhou K; Guo S; Tong S; Sun Q; Li F; Zhang X; Qiao Y; Liang G Stem Cells Dev; 2018 Sep; 27(17):1191-1202. PubMed ID: 29978730 [TBL] [Abstract][Full Text] [Related]
73. The Roles of Programmed Cell Death Ligand-1/ Programmed Cell Death-1 (PD-L1/PD-1) in HPV-induced Cervical Cancer and Potential for their Use in Blockade Therapy. Zhang L; Zhao Y; Tu Q; Xue X; Zhu X; Zhao KN Curr Med Chem; 2021; 28(5):893-909. PubMed ID: 32003657 [TBL] [Abstract][Full Text] [Related]
74. PD-L1 Ameliorates Murine Acute Graft-Versus-Host Disease by Suppressing Effector But Not Regulatory T Cells Function. Tang L; Ma S; Gong H; Wang J; Xu Y; Wu D; Sun A Arch Immunol Ther Exp (Warsz); 2019 Jun; 67(3):179-187. PubMed ID: 30927016 [TBL] [Abstract][Full Text] [Related]
75. Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression. Zheng NN; Zhou M; Sun F; Huai MX; Zhang Y; Qu CY; Shen F; Xu LM World J Gastroenterol; 2020 Jul; 26(26):3737-3749. PubMed ID: 32774054 [TBL] [Abstract][Full Text] [Related]
76. Water extract of sporoderm-broken spores of Ganoderma lucidum enhanced pd-l1 antibody efficiency through downregulation and relieved complications of pd-l1 monoclonal antibody. He J; Zhang W; Di T; Meng J; Qi Y; Li G; Zhang Y; Su H; Yan W Biomed Pharmacother; 2020 Nov; 131():110541. PubMed ID: 33152901 [TBL] [Abstract][Full Text] [Related]
77. Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity. Gianchecchi E; Delfino DV; Fierabracci A Autoimmun Rev; 2013 Sep; 12(11):1091-100. PubMed ID: 23792703 [TBL] [Abstract][Full Text] [Related]
78. Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo. Liu X; He S; Wu H; Xie H; Zhang T; Deng Z Environ Health Prev Med; 2019 Dec; 24(1):79. PubMed ID: 31864288 [TBL] [Abstract][Full Text] [Related]
79. PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer. Diskin B; Adam S; Cassini MF; Sanchez G; Liria M; Aykut B; Buttar C; Li E; Sundberg B; Salas RD; Chen R; Wang J; Kim M; Farooq MS; Nguy S; Fedele C; Tang KH; Chen T; Wang W; Hundeyin M; Rossi JAK; Kurz E; Haq MIU; Karlen J; Kruger E; Sekendiz Z; Wu D; Shadaloey SAA; Baptiste G; Werba G; Selvaraj S; Loomis C; Wong KK; Leinwand J; Miller G Nat Immunol; 2020 Apr; 21(4):442-454. PubMed ID: 32152508 [TBL] [Abstract][Full Text] [Related]
80. Delicate Role of PD-L1/PD-1 Axis in Blood Vessel Inflammatory Diseases: Current Insight and Future Significance. Veluswamy P; Wacker M; Scherner M; Wippermann J Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33142805 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]